# Advisor Review - Advisor 2/3

**Role:** Academic advisor checking for fatal errors
**Model:** gpt-5.2-2025-12-11
**Paper:** paper.pdf
**Reasoning effort:** high
**Timestamp:** 2026-01-29T18:56:44.810742
**Response ID:** resp_05ce73aecc86bd3d00697b9eb491548193aa1b094e6cd9012a
**Tokens:** 19365 in / 4344 out
**Response SHA256:** 4caeb2c43e5656d7

---

I checked the draft **only** for fatal, submission-blocking problems in the four categories you listed (data–design alignment, regression sanity, completeness, internal consistency). I did **not** assess writing, novelty, or minor modeling choices.

## 1) DATA–DESIGN ALIGNMENT (CRITICAL)

### (a) Treatment timing vs. data coverage
- **Application-based BFS series (BA/HBA/WBA/CBA):** stated coverage **2005–2024** (annualized from monthly).  
  - Latest treatment cohort is **2024 (OH retail sales 2024)**.  
  - **Max(treatment year)=2024 ≤ Max(data year)=2024** → **OK**.
- **BF8Q series:** stated coverage **2005–2020** with an unbalanced panel.  
  - You explicitly note that only cohorts through ~2020 can contribute post-treatment BF8Q observations → **OK**, and you flag the causal-timing problem (see below).

### (b) Post-treatment observations by cohort
- For the main outcomes (applications): each cohort has some post-treatment years, though **2024 has only one post year (2024)**. That’s not a fatal error for DiD; it just limits precision.
- For BF8Q: you correctly acknowledge limited post-period support and treat BF8Q as **non-causal/descriptive** → not a fatal design inconsistency.

### (c) Treatment definition consistency
- Treatment is consistently defined as **first legal recreational retail sales year** (Table 1; text; equations; figures). No internal contradiction found.

**No fatal data–design misalignment found.**

## 2) REGRESSION SANITY (CRITICAL)

I scanned the reported regression tables for broken outputs.

- **Table 3 (TWFE):** coefficients around −0.07 with SE ≈ 0.04; R² in [0.927, 0.990]; N=1,020 → **sane**.
- **Table 4 (Callaway–Sant’Anna):** overall ATT −0.028 (SE 0.030) → **sane**. Cohort SEs are not absurdly large; no “Inf/NaN”.
- **Table 5 (TWFE across BFS series):** coefficients small; SEs reasonable (largest SE 0.070 for corporate applications). BF8Q coefficient 0.030 (SE 0.018), N=623, R²=0.962 → **sane**.
- No impossible R², negative SEs, wildly huge coefficients, or SEs that scream collinearity artifacts.

**No fatal regression-output sanity issues found.**

## 3) COMPLETENESS (CRITICAL)

- Regression tables shown include **standard errors and N**.
- No “TBD/TODO/XXX/NA/NaN/Inf” placeholders detected in the pasted content.
- Robustness procedures mentioned (randomization inference; pairs cluster bootstrap; medical-only controls; excluding COVID years) are **reported with p-values / estimates** (Table 6 + text).
- Figures referenced (1–6) appear to exist in the provided excerpt (main + appendix).

**No fatal incompleteness found.**

## 4) INTERNAL CONSISTENCY (CRITICAL)

- Key numbers quoted in text match the tables shown (e.g., TWFE −0.068; RI p=0.093; bootstrap p=0.064; BF8Q +0.030).
- You consistently warn that **BF8Q cannot be interpreted causally** under your DiD timing—this prevents an internal-consistency failure (you do not overclaim it as causal).
- Sample periods are consistently described: application outcomes use 2005–2024; BF8Q uses 2005–2020.

**No fatal internal inconsistencies found.**

ADVISOR VERDICT: PASS